Table 4 Demographics, CUP classification and genomic results of 14 patients treated with targeted therapy.
From: Six-year experience of Australia’s first dedicated cancer of unknown primary clinic
Age | Sex | CUP subtype | CUP subtype detail | Molecular target identified | Molecular target detail | Targeted therapy |
|---|---|---|---|---|---|---|
60 | M | Favourable | Renal-like | No | — | Pazopanib |
59 | M | Favourable | Lung-like | Yes | EGFR exon 18 mutation | Erlotinib |
63 | M | Favourable | Colon-like | No | — | Regorafenib |
56 | F | Favourable | Breast-like | Yes | ERBB2 amplification | Trastuzumab and pertuzumab |
73 | F | Favourable | Breast-like | Yes | ERBB2 amplification | Trastuzumab and pertuzumab |
60 | F | Unfavourable | — | Yes | MYC amplification | BET inhibitor |
70 | M | Unfavourable | — | Yes | BRCA2 mutation | Talazoparib |
64 | F | Unfavourable | — | No | — | Pazopanib |
69 | F | Favourable | Renal-like | No | — | Pazopanib |
64 | M | Unfavourable | — | Yes | CDK3 mutation | Ribociclib and trametinib |
71 | M | Favourable | Renal-like | No | — | Pazopanib |
24 | F | Unfavourable | — | Yes | PIK3CA and PTEN alterations | Ipatasertib |
48 | M | Unfavourable | — | Yes | BRAF mutation | Vemurafenib |
39 | F | Unfavourable | — | Yes | ERBB2 amplification | Trastuzumab, Ado-trastuzumab emtansine |
